MetaVia MTVA
NASDAQ MTVA
$1.46 +0.02 (+1.39%)
At close: Aug 21, 2026 · 4:00 PM EDT

MetaVia (MTVA) Change in Accured Expenses (2015 - 2025)

MetaVia's (MTVA) quarterly Change in Accured Expenses came in at -$1.2 million in Q4 2025, up 65.62% YoY from -$727566.8 in Q4 2024, and down 657.86% on a QoQ basis from -$159000.0 in Q3 2025.

MetaVia (MTVA) Change in Accured Expenses (2015 - 2025) Analysis & Trends

MetaVia (MTVA) has 11 years of Change in Accured Expenses data on file, last reported at -$1.2 million in Q4 2025.

  • Quarterly Change in Accured Expenses rose 65.62% year-over-year to -$1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $431000.0 (up 193.49% YoY) and the FY2025 annual result came in at $431000.0, up 193.49% from the prior year.
  • Change in Accured Expenses slipped to -$1.2 million in Q4 2025, from -$159000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.8 million in Q4 2023 to a low of -$3.5 million in Q4 2024.
  • A 5-year average of $166800.0 and a median of -$2000.0 in 2021 frame the typical range for Change in Accured Expenses.
  • Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 1663.3% — and 2024, when it tumbled 440.88%.
  • Tracing MTVA's Change in Accured Expenses over 5 years: stood at $374000.0 in 2021, then plunged by 151.07% to -$191000.0 in 2022, then soared by 1568.06% to $2.8 million in 2023, then sank by 225.0% to -$3.5 million in 2024, then surged by 65.62% to -$1.2 million in 2025.
  • The last three Change in Accured Expenses figures came in at -$1.2 million (Q4 2025), -$159000.0 (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 11.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 212.44 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 61.62 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 68.82 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 MetaVia 8.72 Mn -3.92 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -1.21 Mn
Dec 31, 2025 -1.21 Mn
Sep 30, 2025 -159,000.00
Sep 30, 2025 -159,000.00
Jun 30, 2025 1.45 Mn
Jun 30, 2025 1.45 Mn
Mar 31, 2025 348,000.00
Mar 31, 2025 348,000.00
Dec 31, 2024 -3.51 Mn
Dec 31, 2024 -3.51 Mn
Sep 30, 2024 1.31 Mn
Sep 30, 2024 1.31 Mn
Jun 30, 2024 2.20 Mn
Jun 30, 2024 2.20 Mn
Mar 31, 2024 -467,000.00
Mar 31, 2024 -467,000.00
Dec 31, 2023 2.80 Mn
Dec 31, 2023 2.80 Mn
Sep 30, 2023 -431,000.00
Sep 30, 2023 -431,000.00